Potent inhibition of nitroglycerin bioactivation by diphenyleneiodonium (DIP) by Regina Neubauer et al.
POSTER PRESENTATION Open Access
Potent inhibition of nitroglycerin bioactivation by
diphenyleneiodonium (DIP)
Regina Neubauer1, Andrea Neubauer1, Gerald Wölkart1, Christine Schwarzenegger1, Barbara Lang1, Kurt Schmidt1,
Michael Russwurm2, Doris Koesling2, Antonius CF Gorren1, Astrid Schrammel1, Bernd Mayer1*
From 6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Erfurt, Germany. 28-30 June 2013
Background
Aldehyde dehydrogenase-2 (ALDH2) catalyzes vascular
bioactivation of the antianginal drug nitroglycerin (GTN)
to yield nitric oxide (NO) or a related species that activates
soluble guanylate cyclase (sGC), resulting in cGMP-
mediated vasodilation [1]. Accordingly, established ALDH2
inhibitors attenuate GTN-induced vasorelaxation in vitro
and in vivo. However, the ALDH2 hypothesis has not been
reconciled with early studies demonstrating potent inhibi-
tion of the GTN response by diphenyleneiodonium (DPI)
[2], a widely used inhibitor of flavoproteins, in particular
NADPH oxidases. We addressed this issue and investigated
the effects of DPI on GTN-induced relaxation of rat aortic
rings and the function of purified ALDH2.
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Figure 1 Effects of DPI on GTN-triggered activation of sGC in the presence of purified ALDH2. Purified sGC was incubated at 37°C for 10 min
with 4 µg of ALDH2 in the presence of 0.5 mM [a-32P]GTP, 1,000 units/ml SOD, and 1 mM NAD+ with DPI, GTN or DEA/NO as indiacted,
followed by isolation of 32P-cGMP and determination of radioactivity by liquid scintillation counting. A: Effects of the indicated concentrations of
DPI on sGC activity determined in the presence of GTN or DEA/NO (1 µM each). B: Activation of sGC by increasing concentrations of GTN in the
absnece and presence of 10 µM DPI. The data are mean values ± S.E.M. (n=3-4).
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Results
DPI (0.3 µM) inhibited the high affinity component of aor-
tic relaxation to GTN without affecting the response to
NO, indicating that the drug interfered with GTN bioacti-
vation. As shown in Figure 1A, DPI inhibited bioactivation
of GTN (1 µM) by ALDH2, assayed as activation of puri-
fied sGC, with an IC50 of 0.20 ± 0.03 µM, whereas cGMP
formation induced by the NO donor DEA/NO was not
affected. DPI (10 µM) caused a pronounced right-ward
shift of the GTN concentration response (Figure 1B), indi-
cating that the drug acts in a GTN-competitive manner.
The effect on GTN bioactivation was accompanied
by GTN-competitive inhibition of 1,2-glycerol dinitrate
formation (IC50 0.21±0.04 µM in the presence of 2 µM
GTN). DPI also inhibited the established dehydrogenase
and esterase activities of ALDH2 with similar potency,
again in a substrate-competitive manner. This was con-
firmed by molecular modeling, suggesting overlapping
binding sites of DPI and GTN in the catalytic site of the
enzyme (Figure 2). In contrast to ALDH2, ALDH1 and
alcohol dehydrogenase were only partially (ALDH1) or not
at all (ADH) inhibited by up to 0.1 mM DPI.
Conclusion
The identification of DPI as potent ALDH2 inhibitor
may have implications beyond the cardiovascular phar-
macology of organic nitrates. A well established function
of ALDH2 is detoxification of reactive aldehydes in liver
and heart. NADPH oxidase activation has been impli-
cated in both alcohol-induced liver injury and cardiac
dysfunction. In view of the present results, showing that
DPI potently inhibits the various enzymatic functions of
ALDH2, it may be necessary to revise some of the ear-
lier conclusions that are based on inhibitory effects of
aryliodonium compounds.
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Figure 2 Model of DPI binding to ALDH2. A: Stereoscopic representation of the active site of ALDH2 (green) in complex with DPI (blue). The
enzyme is shown as cartoon and active site residues and DPI are shown as sticks. B: Superposition of the modelled ALDH2-complex with DPI
and the experimentally determined structure of GTN-bound ALDH2 (pdb-code 4fr8). The enzyme is shown as cartoon (green), Cys-302, DPI
(blue), and GTN (red) are shown as sticks.
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